Propolis Xylitol Oral Formulation for Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies lack an effective, definitive solution for the prevention and treatment of COVID-19, particularly in reducing the viral load in the oral and nasal areas, which is crucial for decreasing the severity of the disease and reducing transmission risks.
Innovation Solution
A novel formulation combining bee propolis and xylitol, tested at specific concentrations, is developed to provide antiviral protection, potentially usable as a dental or nasal product, with propolis ranging from 0.25% to 2.00% and xylitol from 0.25% to 3.0%, alongside other agents like barbadensis leaf juice, hydroxyethyl cellulose, and sodium lauryl sulfoacetate, to create a protective barrier and inhibit viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional mouthwashes like chlorhexidine are used, then viral load decreases transiently, but it increases again within 2-4 hours and provides no definitive cure
Solution Approach 1:
The patent combines multiple active ingredients (propolis extract, xylitol, and other botanical extracts) into a composite oral formulation. This composite approach creates synergistic effects that provide sustained viral load reduction without the rebound effect observed with single-agent chlorhexidine, addressing both duration and reliability of action.
Solution Approach 2:
The formulation uses specific concentration ranges of propolis (0.25-2.00%) and xylitol (0.25-3.0%) to optimize antiviral activity. By carefully controlling these parameters, the formulation achieves prolonged viral load suppression and sustained protective effect up to 4 days, resolving the transient action problem of conventional mouthwashes.
2Object-affected harmful factors
If high concentrations of antiviral agents are used, then viral replication is inhibited more effectively, but cytotoxicity to oral cells increases
Solution Approach 1:
The patent identifies optimal concentration ranges for propolis (0.25-2.00%) and xylitol (0.25-3.0%) that maximize antiviral activity while maintaining safety. These parameter optimizations ensure effective viral replication inhibition without exceeding cytotoxic thresholds, resolving the contradiction between efficacy and safety.
Solution Approach 2:
Xylitol serves as a safe intermediary substance that enhances the antiviral activity of propolis while itself being non-cytotoxic. This mediator approach allows the formulation to achieve strong viral replication inhibition through synergistic interaction, avoiding the need for high concentrations of potentially toxic antiviral agents.
3Reliability
If the formulation uses multiple active ingredients, then antiviral effectiveness is enhanced, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The formulation uses propolis and xylitol as multi-functional ingredients that simultaneously provide antiviral activity, anti-inflammatory effects, and oral tissue protection. This multi-functionality reduces the need for multiple separate ingredients, simplifying the formulation while maintaining enhanced antiviral effectiveness.
Data Source
AI summary
A novel formulation for the prevention and treatment of COVID-19 is disclosed, featuring the antiviral properties of xylitol and bee propolis. These natural compounds were tested against porcine coronavirus (PEDV), human OC43 virus, and SARS-CoV-2. Notably, propolis and xylitol showed protective effects at concentrations below cytotoxic levels. The formulation is presented as a dental product with propolis (0.25-2.00 wt. %) and xylitol (0.25-3.0 wt. %) alongside various agents for oral and nasal applications. These findings suggest a promising approach to combat coronaviruses and provide an inventive solution for COVID-19 prevention and treatment.